Imatinib-Resistenz eines metastasierten GIST - Zweiter Kommentar

Literatur

• 1 Verweij J, Casali P G, Zalcberg J, LeCesne A, Reichardt P, Blay J Y, Issels R, van Oosterom A, Hogendoorn P C, Van Glabbeke M, Bertulli R, Judson I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.  Lancet. 2004;  364 1127-1134
• 2 Van Glabbeke M, Verweij J, Casali P G, Zalcberg J, Le C esne, Hohenberger P. et al . Initial and late resistance to imatinib in advanced gastro-intestinal stromal tumors (GIST) are predicted by different prognsotic factors.  J Clin Oncol. 2005;  (in press)
• 3 Debiec-Rychter M, Sciot R, Verweij J, Casali P, LeCesne A, Zalcberg J, Hohenberger P, Blay J Y, Schlemmer M, VanGlabbeke M. et al . KIT mutations should guide dose selection for imatinib in patients with advanced gastrointestinal stromal tumors. Results of mutation analysis in 377 patients entered into a randomized study.  Nature Med. ;  (submitted)
• 4 Stroszczynski C, Jost D, Reichardt P, Chmelik P, Gaffke G, Schlecht I, Kretzschmar A, Schneider U, Hohenberger P. Follow-up of imatinib treatment of GI stromal tumors with abdominal MRI.  Eur Radiol. 2005;  (accepted for publication)
• 5 Hohenberger P, Schneider U, Rötzschke O, Kettelhack C, Pink D, Wardelmann E, Reichardt P. Resection of progressive or residual tumor following treatment with imatinib for advanced GI stromal tumors.  Ann Surg Oncol. 2005;  5 (in press)
• 6 Demetri G, Desai J, Fletcher J A, Morgan J A, Fletcher C DM, Kazanovicz A, van den Abbeele A, Baum C, Maki R, Heinrich M. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST).  Proc Am Soc Clin Oncol. 2004;  22(14S) 3001